BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 19144441)

  • 1. DNA methylation in small lung adenocarcinoma with bronchioloalveolar carcinoma components.
    Kubo T; Yamamoto H; Ichimura K; Jida M; Hayashi T; Otani H; Tsukuda K; Sano Y; Kiura K; Toyooka S
    Lung Cancer; 2009 Sep; 65(3):328-32. PubMed ID: 19144441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers.
    Toyooka S; Tokumo M; Shigematsu H; Matsuo K; Asano H; Tomii K; Ichihara S; Suzuki M; Aoe M; Date H; Gazdar AF; Shimizu N
    Cancer Res; 2006 Feb; 66(3):1371-5. PubMed ID: 16452191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promoter hypermethylation profile of ovarian epithelial neoplasms.
    Makarla PB; Saboorian MH; Ashfaq R; Toyooka KO; Toyooka S; Minna JD; Gazdar AF; Schorge JO
    Clin Cancer Res; 2005 Aug; 11(15):5365-9. PubMed ID: 16061849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
    Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
    Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.
    Nakata S; Sugio K; Uramoto H; Oyama T; Hanagiri T; Morita M; Yasumoto K
    Cancer; 2006 May; 106(10):2190-9. PubMed ID: 16598757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma.
    Hsu HS; Chen TP; Hung CH; Wen CK; Lin RK; Lee HC; Wang YC
    Cancer; 2007 Nov; 110(9):2019-26. PubMed ID: 17876837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological and molecular evidence indicating the independence of bronchioloalveolar components from other subtypes of human peripheral lung adenocarcinoma.
    Koga T; Hashimoto S; Sugio K; Yoshino I; Mojtahedzadeh S; Matsuo Y; Yonemitsu Y; Sugimachi K; Sueishi K
    Clin Cancer Res; 2001 Jun; 7(6):1730-8. PubMed ID: 11410513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA methylation of multiple genes and clinicopathological relationship of non-small cell lung cancers.
    Hanabata T; Tsukuda K; Toyooka S; Yano M; Aoe M; Nagahiro I; Sano Y; Date H; Shimizu N
    Oncol Rep; 2004 Jul; 12(1):177-80. PubMed ID: 15201980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological significance of aberrant methylation of RARbeta2 at 3p24, RASSF1A at 3p21.3, and FHIT at 3p14.2 in patients with non-small cell lung cancer.
    Tomizawa Y; Iijima H; Nomoto T; Iwasaki Y; Otani Y; Tsuchiya S; Saito R; Dobashi K; Nakajima T; Mori M
    Lung Cancer; 2004 Dec; 46(3):305-12. PubMed ID: 15541815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer.
    Fujiwara K; Fujimoto N; Tabata M; Nishii K; Matsuo K; Hotta K; Kozuki T; Aoe M; Kiura K; Ueoka H; Tanimoto M
    Clin Cancer Res; 2005 Feb; 11(3):1219-25. PubMed ID: 15709192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant promoter hypermethylation in serum DNA from patients with silicosis.
    Umemura S; Fujimoto N; Hiraki A; Gemba K; Takigawa N; Fujiwara K; Fujii M; Umemura H; Satoh M; Tabata M; Ueoka H; Kiura K; Kishimoto T; Tanimoto M
    Carcinogenesis; 2008 Sep; 29(9):1845-9. PubMed ID: 18632757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic and epigenetic alterations in lung tumors from bitransgenic Ki-rasG12C expressing mice.
    Floyd HS; Jennings-Gee JE; Kock ND; Miller MS
    Mol Carcinog; 2006 Jul; 45(7):506-17. PubMed ID: 16482519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of p16(INK4a) hypermethylation in non-small cell lung cancer is evident by quantitative DNA methylation analysis.
    Ota N; Kawakami K; Okuda T; Takehara A; Hiranuma C; Oyama K; Ota Y; Oda M; Watanabe G
    Anticancer Res; 2006; 26(5B):3729-32. PubMed ID: 17094392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methylation assay for the diagnosis of lung cancer on bronchial aspirates: a cohort study.
    Schmiemann V; Böcking A; Kazimirek M; Onofre AS; Gabbert HE; Kappes R; Gerharz CD; Grote HJ
    Clin Cancer Res; 2005 Nov; 11(21):7728-34. PubMed ID: 16278393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of function of p16 gene and prognosis of pulmonary adenocarcinoma.
    Tanaka R; Wang D; Morishita Y; Inadome Y; Minami Y; Iijima T; Fukai S; Goya T; Noguchi M
    Cancer; 2005 Feb; 103(3):608-15. PubMed ID: 15612080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SCCRO expression correlates with invasive progression in bronchioloalveolar carcinoma.
    Sarkaria IS; Pham D; Ghossein RA; Talbot SG; Hezel M; Dudas ME; Ebright MI; Chuai S; Memoli N; Venkatraman ES; Miller VA; Kris MG; Zakowski MF; Rusch VW; Singh B
    Ann Thorac Surg; 2004 Nov; 78(5):1734-41. PubMed ID: 15511464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p16INK4A and CDH13 hypermethylation in tumor and serum of non-small cell lung cancer patients.
    Ulivi P; Zoli W; Calistri D; Fabbri F; Tesei A; Rosetti M; Mengozzi M; Amadori D
    J Cell Physiol; 2006 Mar; 206(3):611-5. PubMed ID: 16222700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of p16 homozygous deletions with clinicopathologic characteristics and EGFR/KRAS/p53 mutations in lung adenocarcinoma.
    Iwakawa R; Kohno T; Anami Y; Noguchi M; Suzuki K; Matsuno Y; Mishima K; Nishikawa R; Tashiro F; Yokota J
    Clin Cancer Res; 2008 Jun; 14(12):3746-53. PubMed ID: 18559592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Micropapillary pattern: a distinct pathological marker to subclassify tumours with a significantly poor prognosis within small peripheral lung adenocarcinoma (Makimoto Y; Nabeshima K; Iwasaki H; Miyoshi T; Enatsu S; Shiraishi T; Iwasaki A; Shirakusa T; Kikuchi M
    Histopathology; 2005 Jun; 46(6):677-84. PubMed ID: 15910599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic evolution of epidermal growth factor receptor in adenocarcinoma with a bronchioloalveolar carcinoma component.
    Zhong WZ; Wu YL; Yang XN; Guo AL; Su J; Zhang XC; Luo DL; Wang Z; Chen HJ; Zhou Q; Xu CR; Qiao GB; Liao RQ; Yang JJ; Mok TS
    Clin Lung Cancer; 2010 May; 11(3):160-8. PubMed ID: 20439191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.